

## 2 Select the baseline immunosuppressive therapy at time of rejection

- Azathioprine
- Cyclosporine
- Everolimus
- Immune globulin
- Methotrexate
- Mycophenolate
- Plasmapheresis
- Prednisone
- Rituximab
- Sirolimus
- Tacrolimus
- Cytoxan (cyclophosphamide)
- Unknown
- Other, specify

## Biopsy Prior to Rejection Event

### 3 Biopsy Performed Prior to Rejection Event

If performed prior to this rejection diagnosis, indicate the score of the most recent biopsy performed that did not lead to rejection treatment.

- No
- Yes

### 3 Biopsy Date Prior to Rejection

MM/DD/YYYY

Missing Reason:

- Unknown

### 3 ACR Score

2004 revised ISHLT scoring system for ACR: (J Heart Lung Transplant. 2005 Nov;24(11):1710-20.)  
ACR: acute cellular rejection (0, 1R, 2R, 3R)

- 0
- 1R
- 2R
- 3R
- Unknown

### 3 AMR Score

2013 revised ISHLT scoring system for pAMR: J Heart Lung Transplant 2013 Dec 32(12):1147-62.)  
pAMR: pathologic antibody mediated rejection (0, 1h, 1i, 2, 3)

- Both histology and immunofluorescence/immunohistochemistry performed (ie. C4d or C3d)
- Did not assess biopsy for evidence of AMR
- Only assessed histology/ did not perform immunofluorescence/immunohistochemistry (ie. C4d or C3d)
- Unknown

### 3 AMR Findings

If only assessed histology/ did not perform immunofluorescence or immunohistochemistry (ie. C4d or C3d)

- No histologic features AMR
- Positive histologic features AMR (ie. Vasculitis/pericapillaritis)

- 0 (negative)

3

**pAMR score**

2013 revised ISHLT scoring system for pAMR:  
J Heart Lung Transplant 2013 Dec 32(12):1147-62.)

pAMR: pathologic antibody mediated rejection (0, 1h, 1i, 2, 3)

- 1h
- 1i
- 2
- 3
- Positive for AMR but pAMR score not known

## Rejection Events

Start with newly diagnosed rejection by biopsy (convert to ISHLT score) or other criteria leading to bolus immunotherapy. List all follow-up biopsies or changes in therapy. The last entry should be the first biopsy or echo not prompting additional therapy. Enter each subsequent rejection event until episode is resolved.

4

**Was donor specific Ab testing performed at the time of the rejection event**

- No, Did not send testing for any circulating antibodies
- Yes
- Unknown

4

**Which antibodies were tested and what were the results**

- HLA class I and/or class II DSA
- Isoagglutinin (A or B Ab) to ABO-i graft
- Non-HLA antibody (e.g. MICA, MICB, anti-endothelial, vimentin, anti-myosin, angiotensin receptor (AR1T), or other non-HLA
- Unknown

4

**HLA Class I and/or II DSA Result**

- Negative
- Positive
- Unknown

**HLA class I and/or II DSA Result, Positive**

- Complement fixing (C1q positive)
- Increased from last date tested
- New
- Present but stable (no new abs and not increased from baseline)
- Unknown

4

**Non-HLA Ab Result**

Non-HLA antibody (e.g. MICA, MICB, anti-endothelial, vimentin, anti-myosin, angiotensin receptor (AR1T), or other non-HLA Results

- Negative
- Positive
- Unknown

**Non-HLA Ab Result, Positive**

Non-HLA antibody (e.g. MICA, MICB, anti-endothelial, vimentin, anti-myosin, angiotensin receptor (AR1T), or other non-HLA Results

- Increased from last date tested
- New
- Present but stable (no new abs and not increased from baseline)
- Unknown

4

**Isoagglutinin (A or B Ab) to ABO-i graft**

Positive is defined as titer of 1:16 or higher

- Negative
- Positive
- Unknown

### Rejection Event

**Date of rejection event**

Any episode leading to an increase in immunotherapy to treat a biopsy or clinically diagnosed episode of rejection  
MM/DD/YYYY

5a

**Basis for Diagnosis of Current Rejection Event**

- Biopsy
- Clinical
- ECHO
- New or increased Abs
- Unknown

5b

**Was biopsy performed?**

- No
- Yes

5b

**Indication for biopsy**

Check all that apply.

- Objective Evidence of Graft Dysfunction
- Research
- Routine (scheduled as part of protocol surveillance)
- Symptoms

5b

**ACR Grading**

2004 revised ISHLT scoring system for ACR:  
(J Heart Lung Transplant. 2005 Nov;24(11):1710-20.)  
ACR: acute cellular rejection (0, 1R, 2R, 3R)

- 0
- 1R
- 2R
- 3R
- Unknown

5b

**AMR Grading**

2013 revised ISHLT scoring system for pAMR:  
J Heart Lung Transplant 2013 Dec 32(12):1147-62.)  
pAMR: pathologic antibody mediated rejection (0, 1h, 1i, 2, 3)

- Both histology and immunofluorescence/immunohistochemistry performed (ie. C4d or C3d)
- Did not assess biopsy for evidence of AMR
- Only assessed histology/ did not perform immunofluorescence/immunohistochemistry (ie. C4d or C3d)
- Unknown

5b

**Histology results**

- No histologic features AMR
- Positive histologic features AMR

5b

**If both histology and immunofluorescence/immunohistochemistry performed, indicate pAMR score**

2013 revised ISHLT scoring system for pAMR:  
J Heart Lung Transplant 2013 Dec 32(12):1147-62.)  
pAMR: pathologic antibody mediated rejection (0, 1h, 1i, 2, 3)

- 0
- 1h
- 1i
- 2
- 3
- Positive with Unknown Score

5c

**Was there therapy used to treat this rejection episode?**

If no rejection therapy was used, no more rejection episodes should be entered for this event.

- No
- Yes

5c

**Select the therapy used**

- ATG or ATGAM
- Bortezomib

- Eculizumab
- Immune Adsorption
- Immunoglobulin
- Methotrexate
- Photopheresis
- Plasmapheresis
- Rituximab
- Steroid Taper
- Steroids, IV
- Steroids, Oral
- Tacrolimus
- Cytoxan (cyclophosphamide)
- Other, specify

5d

**Was episode of rejection associated with hemodynamic compromise?**

- Inotropic Support
- Mild
- None
- Unknown

**None** - No significant change in cardiac function at the time of rejection

**Mild** - Worsening of cardiac function detected (decreased ejection fraction,

hypotension, EKG changes) not requiring inotropes.

**Severe Inotropic support** added due to this rejection episode.

6

**Indicate date of the end of the rejection episode**

MM/DD/YYYY

7

**Was there baseline immunosuppressive therapy at time of resolution of rejection event**

- No
- Yes

**7 Baseline immunosuppressive therapy at time of resolution of rejection event**

- Azathioprine (Imuran)
- Cyclosporine (Sandimmune, Neoral, Gengraf, CSA, CyA)
- Everolimus
- Immune globulin
- Methotrexate
- Mycophenolate (Cellcept, Myfortic)
- Prednisone
- Rituximab
- Sirolimus (Rapamycin, Rapamune)
- Tacrolimus (Prograf, FK506)
- Cytoxan (Cyclophosphamide)
- Unknown
- Other, Specify

© 2016 PHTS  
[test]